Four years af­ter it im­plod­ed at Sanofi, John Hood is res­ur­rect­ing the myelofi­bro­sis drug fe­dra­tinib

Fe­dra­tinib was one of the biggest clin­i­cal drug dis­as­ters that oc­curred at Sanofi un­der the tu­mul­tuous reign of CEO Chris Viehbach­er. But af­ter im­plod­ing with spec­tac­u­lar ef­fect right at the thresh­old of a new drug ap­pli­ca­tion four years ago, one of the drug’s co-in­ven­tors — a sci­en­tist named John Hood — has pa­tient­ly picked up all the shat­tered pieces and put it to­geth­er in­to a new com­pa­ny that just scored a $22.5 mil­lion ven­ture round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER